“I have worked closely with Michael for the past 13 years. It is my distinct pleasure to give him my highest recommendation. Michael was a leader at Arena Pharmaceuticals, heading up a team of DMPK experts supporting multiple pre-clinical and clinical development programs. In my position as a pre-clinical program leader I relied on him constantly for pharmacokinetics, metabolism, tolerability, PK/PD, modeling and organizational support. Micheal's contributions to the team were essential for success in many ways; practical, conceptual, integrative, methodological, and strategic. All of these attributes were extremely important in a fast paced biotech setting, but the most impacting of Michael's skills is his attitude. More than any member of any project team, he is missed the most.”
Michael E. Morgan, Ph.D.
San Diego, California, United States
607 followers
500+ connections
San Diego, California, United States
607 followers
500+ connections
About
I am personable, highly motivated and a self-titled science geek. Over 15+ years, I have…
Activity
-
Excited to announce that I have joined Calidi Biotherapeutics as Head of Quality Assurance, Associate Vice President, QA. Looking forward to…
Excited to announce that I have joined Calidi Biotherapeutics as Head of Quality Assurance, Associate Vice President, QA. Looking forward to…
Liked by Michael E. Morgan, Ph.D.
-
Our General Counsel, Robert Mino, joined the Cybin family in November 2020. Rob loves time with family, volunteers with several community…
Our General Counsel, Robert Mino, joined the Cybin family in November 2020. Rob loves time with family, volunteers with several community…
Liked by Michael E. Morgan, Ph.D.
-
This weekend, join Chief Clinical Officer Dr. Alex Belser at the Sana Symposium. Cybin is honored to be featured as a gold sponsor of this event…
This weekend, join Chief Clinical Officer Dr. Alex Belser at the Sana Symposium. Cybin is honored to be featured as a gold sponsor of this event…
Liked by Michael E. Morgan, Ph.D.
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
Volunteer Experience
Publications
-
3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology
J Pharmacol Exp Ther. 331(1):96-103, 2009
-
An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension
J Med Chem. 60(3):913-927, 2017
-
Antithrombotic and vascular effects of AR246686, a novel 5-HT2A receptor antagonist
Eur J Pharmacol 31:586(1-3) 234-243, 2007
-
Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate‑1 Receptor
ACS Med. Chem. Lett, 5 (12):1313-1317, 2014
-
Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control
Bioorg Med Chem Lett. 22 (4): 1750-1755, 2012
-
Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119
J Med Chem. 51(17):5172-5175, 2008
-
Investigating interactions between phentermine, dexfenfluramine, and 5-HT2C agonists, on food intake in the rat
Psychopharmacology: 232(11):1973-82, 2015
-
Lorcaserin (APD356), a Selective 5-HT2C Agonist, Reduces Body Weight in Obese Men and Women
Obesity (2008) doi:10.1038/oby.2008.537
-
Lorcaserin, A Novel Selective Human 5-HT2C Agonist: In Vitro and in Vivo Pharmacological Characterization J Pharmacol Exp Ther 325: 577-587, 2008.
J Pharmacol Exp Ther 325: 577-587, 2008
-
Nelotanserin, a Novel Selective Human 5-Hydroxytryptamine 2A Inverse Agonist for the Treatment of Insomnia
J Pharmacol. Exp. Ther. 332:281-290, 2010
-
Pharmacokinetics and Safety of Lorcaserin in Special Populations – Elderly Subjects and Subjects With Renal or Hepatic Impairment
Clin Ther. 39(4):837-848, 2017
-
Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation
Bioorg Med Chem Lett. 19(21):6166-6171, 2009
-
Single- and Multiple-Dose Pharmacokinetics of a Lorcaserin Extended-Release Tablet
J Clin Therapeutics, 38: 2227-2238, 2016
-
Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis
J Thromb Haemost. 8(2): 331–340, 2011
Patents
-
MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT
EU Publication No. WO2012/030927
Other inventors -
-
MODULATORS OF GPR119 AND THE TREATMENT OF DISORDERS RELATED THERETO
EU WO2012/040279
Other inventors -
-
Title: PHARMACEUTICAL COMPOSITIONS OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
EU Publication No. WO2007/041409
Other inventors -
Honors & Awards
-
Arena Pharmaceuticals and Merck Research Laboratories Collaboration
-
-
Arena Pharmaceuticals and Ortho McNeil Diabetes Collaboration
-
-
One of the most cited manuscripts in the 30-year history of the Journal of Controlled Release
-
“Biodegradable Block Copolymers for Delivery of Proteins and Water-Insoluble Drugs”, Journal of
Controlled Release. 72, 203-215, 2001 -
Outstanding Paper, Controlled Release Society
-
Approaches Toward the Optimization of CNS
Uptake of anti-AIDS Agents.” J. Controlled Release 19:219-230, 1991
Recommendations received
1 person has recommended Michael E.
Join now to viewMore activity by Michael E.
-
Mankind Pharma announces Rs 100 Crores for COVID warriors and their families. They are our Heroes and our Hope. *Mankind Pharma humbly announces *…
Mankind Pharma announces Rs 100 Crores for COVID warriors and their families. They are our Heroes and our Hope. *Mankind Pharma humbly announces *…
Liked by Michael E. Morgan, Ph.D.
-
Addressing children’s mental health needs changes the trajectory of their lives. Our team of experts provides the ounce of prevention today, so we…
Addressing children’s mental health needs changes the trajectory of their lives. Our team of experts provides the ounce of prevention today, so we…
Liked by Michael E. Morgan, Ph.D.
-
At Neurocrine Biosciences, we are excited to share, especially during Parkinson’s Disease Awareness Month, that the FDA approved ONGENTYS®…
At Neurocrine Biosciences, we are excited to share, especially during Parkinson’s Disease Awareness Month, that the FDA approved ONGENTYS®…
Liked by Michael E. Morgan, Ph.D.
-
#2019ncov #covid19usa #covid19 #coronavirus #diagnostics #medicaldevices
#2019ncov #covid19usa #covid19 #coronavirus #diagnostics #medicaldevices
Liked by Michael E. Morgan, Ph.D.
-
Through the generosity and compassion of thousands, The Avielle Foundation is changing the way we understand violence and compassion through…
Through the generosity and compassion of thousands, The Avielle Foundation is changing the way we understand violence and compassion through…
Liked by Michael E. Morgan, Ph.D.
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More